ATP13A2 variability in Taiwanese Parkinson's disease

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 6, 2011, Pages 720-729

  Chen, Chiung Mei ^a   Lin, Chih Hsin ^a   Juan, Hsueh Fen ^b   Hu, Fen Ju ^c   Hsiao, Ya Chin ^c   Chang, Hsin Yi ^b   Chao, Chih Ying ^c   Chen, I Cheng ^a   Lee, Li Ching ^c   Wang, Tsu Wei ^c   Chen, Ya Tang ^c   Chen, Yi Tsun ^c   Lee Chen, Guey Jen ^c   Wu, Yih Ru ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

ATP13A2; Expression study; Mutation screening; Parkinson's disease; Protein structure modeling

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; CASPASE 3; COMPLEMENTARY DNA; CYCLOHEXIMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; ATP13A2 GENE; CLINICAL FEATURE; COMPUTER MODEL; CORPUS STRIATUM; DNA SEQUENCE; DRUG UPTAKE; ETHNICITY; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYSOSOME; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TAIWAN; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CASPASE 3; CELL LINE, TUMOR; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; PROTON-TRANSLOCATING ATPASES; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TAIWAN;

EID: 80051565486     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31214     Document Type: Article

References (33)

1. Ahlemeyer B, Hühne R, Krieglstein J. 2000. Retinoic acid potentiated the protective effect of NGF against staurosporine-induced apoptosis in cultured chick neurons by increasing the trkA protein expression. J Neurosci Res 60(6): 767-778.
2. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. 2009. Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis 35(3): 385-398.
3. Crosiers D, Ceulemans B, Meeus B, Nuytemans K, Pals P, Van Broeckhoven C, Cras P, Theuns J. 2011. Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism Relat Disord 17(2): 135-138.
4. Dächsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ. 2006. Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2 Neurosci Lett 410(2): 80-84.
5. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER, Italian Parkinson Genetics Network, Bonifati V. 2007. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68(19): 1557-1562.
6. Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. 2009. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 24(14): 2104-2111.
7. Farazi TA, Waksman G, Gordon JI. 2001. The biology and enzymology of protein N-myristoylation. J Biol Chem 276(43): 39501-39504.
8. Fei QZ, Cao L, Xiao Q, Zhang T, Zheng L, Wang XJ, Wang G, Zhou HY, Wang Y, Chen SD. 2010. Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China. Neurosci Lett 475(2): 61-63.
9. Fong CY, Rolfs A, Schwarzbraun T, Klein C, O'Callaghan FJ. 2011. Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation. Eur J Paediatr Neurol 15(3): 271-275.
10. Funayama M, Tomiyama H, Wu RM, Ogaki K, Yoshino H, Mizuno Y, Hattori N. 2010. Rapid screening of ATP13A2 variant with high-resolution melting analysis. Mov Disord 25(14): 2434-2437.
11. Fung HC, Chen CM, Hardy J, Singleton AB, Lee-Chen GJ, Wu YR. 2006. Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. Neurosci Lett 394(1): 33-36.
12. Gelb DJ, Oliver E, Gilman S. 1999. Diagnostic criteria for Parkinson disease. Arch Neurol 56(1): 33-39.
13. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. 2009. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41(3): 308-315.
14. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3): S26-S36.
15. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. 2007. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6(7): 652-662.
16. Kühlbrandt W. 2004. Biology, structure and mechanism of P-type ATPases. Nat Rev Mol Cell Biol 5(4): 282-295.
17. Lesage S, Brice A. 2009. Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1): R48-R59.
18. Lii CK, Hung CN. 1997. Protein thiol modifications of human red blood cells treated with t-butyl hydroperoxide. Biochim Biophys Acta 1336(2): 147-156.
19. Lin CH, Tan EK, Chen ML, Tan LC, Lim HQ, Chen GS, Wu RM. 2008. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology 71(21): 1727-1732.
20. Mao XY, Burgunder JM, Zhang ZJ, Chang XL, Peng R, Burgunder JM, Yang Y, Wang YC, Li T, Zhang ZJ. 2010. ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China. Parkinsonism Relat Disord 16(3): 235-236.
21. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. 1994. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 89(5): 347-352.
22. Ning YP, Kanai K, Tomiyama H, Li Y, Funayama M, Yoshino H, Sato S, Asahina M, Kuwabara S, Takeda A, Hattori T, Mizuno Y, Hattori N. 2008. PARK9-linked parkinsonism in eastern Asia: Mutation detection in ATP13A2 and clinical phenotype. Neurology 70(16 Pt 2): 1491-1493.
23. Paisán-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H. 2010. Early-onset L-DOPA-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25: 1791-1800.
24. Pan T, Kondo S, Le W, Jankovic J. 2008. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131(Pt 8): 1969-1978.
25. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. 2006. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38(10): 1184-1191.
26. Santoro L, Breedveld GJ, Manganelli F, Iodice R, Pisciotta C, Nolano M, Punzo F, Quarantelli M, Pappatà S, Di Fonzo A, Oostra BA, Bonifati V. 2011. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 12(1): 33-39.
27. Schultheis PJ, Hagen TT, O'Toole KK, Tachibana A, Burke CR, McGill DL, Okunade GW, Shull GE. 2004. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem Biophys Res Commun 323(3): 731-738.
28. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, Michel T. 1996. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 271(11): 6518-6522.
29. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med 361(17): 1651-1661.
30. Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH, Xia K, Zhang Z. 2006. Association of PINK1 and DJ-1confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15(11): 1816-1825.
31. Vilariño-Güell C, Soto AI, Lincoln SJ, Ben Yahmed S, Kefi M, Heckman MG, Hulihan MM, Chai H, Diehl NN, Amouri R, Rajput A, Mash DC, Dickson DW, Middleton LT, Gibson RA, Hentati F, Farrer MJ. 2009. ATP13A2 variability in Parkinson disease. Hum Mutat 30(3): 406-410.
32. Wu YR, Wu CH, Chao CY, Kuan CC, Zhang WL, Wang CK, Chang CY, Chang YC, Lee-Chen GJ, Chen CM. 2010. Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9g>a single nucleotide polymorphism and risk of Taiwanese PD. Am J Med Genet Part B 153B(1): 229-234.
33. Zhou C, Huang Y, Przedborski S. 2008. Oxidative stress in Parkinson's disease: A mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147: 93-104.